Researchers Launch Phase 1 Trial of Potential MRSA Treatment

NIAID-funded researchers have launched a Phase 1 clinical trial of the candidate oral antibiotic EDP-788, a drug intended to treat methicillin-resistant Staphylococcus aureus (MRSA) infections. The trial, conducted by biotechnology company Enanta Pharmaceuticals through a contract with NIAID, will evaluate the drug’s safety and how it is broken down and processed in the body.

For more information on EDP-788, MRSA, and the new clinical trial, see the NIAID.

Posted by Tim Sandle